BRNS
Barinthus Biotherapeutics plc NASDAQ Listed Apr 30, 2021$0.67
Mkt Cap $27.4M
52w Low $0.51
6.6% of range
52w High $2.92
50d MA $0.60
200d MA $0.91
P/E (TTM)
-0.4x
EV/EBITDA
0.6x
P/B
0.3x
Debt/Equity
0.1x
ROE
-89.5%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
-0.60
50d MA
$0.60
200d MA
$0.91
Avg Volume
40.2K
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Zeus Building · Didcot, MD OX11 0DF · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.28 | -0.14 | +50.0% | 0.65 | -3.1% | +0.1% | -2.4% | +3.1% | +0.4% | +1.9% | — |
| Mar 13, 2026 | AMC | -0.40 | -0.27 | +32.5% | 0.63 | +1.7% | +8.1% | -0.0% | -6.0% | -1.4% | +0.0% | — |
| Nov 7, 2025 | AMC | -0.45 | -0.36 | +20.0% | 1.07 | +0.9% | -17.8% | -9.1% | +1.1% | -3.3% | +1.7% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.52 | -79.3% | 1.45 | -5.5% | -7.6% | -14.9% | +7.0% | +3.3% | +1.6% | — |
| May 7, 2025 | AMC | -0.34 | -0.49 | -44.1% | 0.99 | -5.1% | -9.1% | -3.7% | +7.3% | -2.2% | -2.2% | — |
| Mar 20, 2025 | AMC | -0.50 | -0.51 | -2.0% | 1.01 | -1.0% | -2.0% | +4.0% | -1.0% | +3.9% | -0.9% | — |
| Nov 6, 2024 | AMC | -0.45 | -0.21 | +53.3% | 1.48 | +0.0% | -0.7% | -8.2% | +1.5% | +2.2% | +0.0% | — |
| Aug 8, 2024 | AMC | -0.42 | -0.43 | -2.4% | 1.38 | -1.4% | -2.2% | -0.7% | -1.5% | +0.0% | -1.5% | — |
| May 13, 2024 | AMC | -0.64 | -0.40 | +37.5% | 2.35 | -1.7% | -1.3% | -3.9% | +9.0% | -3.3% | +2.1% | — |
| Mar 20, 2024 | AMC | -0.55 | -0.45 | +18.2% | 2.45 | -0.4% | -1.6% | +7.1% | -6.6% | -0.4% | -2.9% | — |
| Nov 9, 2023 | AMC | -0.62 | -0.37 | +40.3% | 3.25 | -6.8% | -7.1% | -8.3% | +7.2% | -3.0% | +2.4% | — |
| Aug 10, 2023 | AMC | -0.59 | -0.62 | -5.1% | 2.19 | -0.9% | -5.0% | -3.8% | +1.5% | +2.0% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.80 | $0.80 | +0.6% | -3.2% | -7.3% | +2.4% | -4.6% | +2.7% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.01 | $1.00 | -1.0% | -2.0% | +4.0% | -1.0% | +3.9% | -0.9% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.04 | +1.0% | -8.7% | +0.8% | +7.7% | -1.0% | +3.0% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.84 | $0.88 | +4.9% | +6.1% | +1.2% | +9.9% | -9.5% | +8.9% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.52 | +3.4% | -8.2% | +1.5% | +2.2% | +0.0% | -1.4% |
| Oct 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.20 | +0.8% | -0.8% | +1.7% | +3.3% | +7.3% | -5.3% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.24 | +3.3% | +0.0% | -1.7% | +0.8% | -0.8% | +1.7% |
| Aug 13 | Alliance Global Partners | Maintains | Buy → Buy | — | $1.34 | $1.41 | +5.2% | -1.5% | +0.0% | -1.5% | -3.8% | +1.6% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.35 | +0.0% | -0.7% | -1.5% | +0.0% | -1.5% | -3.8% |
| Jun 13 | Barclays | Maintains | Overweight → Overweight | — | $1.90 | $1.81 | -4.7% | +0.5% | -4.2% | -7.7% | -4.1% | -22.8% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.97 | +3.7% | +4.7% | -4.5% | -3.7% | +3.8% | +0.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.23 | $2.30 | +3.1% | +9.0% | -3.3% | +2.1% | -10.4% | +7.0% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.51 | $2.55 | +1.6% | +4.4% | -2.7% | -1.6% | -3.2% | +2.9% |
| Apr 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.71 | $2.67 | -1.5% | -7.4% | +4.4% | -2.7% | -1.6% | -3.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.45 | $2.44 | -0.4% | -1.6% | +7.1% | -6.6% | -0.4% | -2.9% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.83 | $2.75 | -2.8% | +10.4% | -2.3% | -6.5% | +10.3% | -4.4% |
| Sep 25 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $1.68 | $1.64 | -2.4% | +88.1% | -10.8% | +6.0% | -0.7% | +4.0% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.00 | $1.99 | -0.5% | -1.0% | +0.5% | -1.5% | +0.0% | +0.5% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.46 | +1.7% | +1.2% | -3.3% | +5.1% | -7.6% | -1.7% |
| May 16 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.33 | $2.36 | +1.3% | +1.7% | +0.4% | +3.4% | +0.0% | +2.0% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.45 | +0.8% | +1.6% | -9.7% | +12.1% | -8.0% | -2.6% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.68 | $4.66 | -0.4% | -3.6% | +6.7% | +1.9% | -3.9% | -3.4% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.90 | +5.8% | -7.1% | +8.8% | -3.6% | +6.7% | +1.9% |
| May 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.46 | $4.47 | +0.2% | +1.8% | +1.3% | -7.6% | +7.3% | -12.3% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.09 | $3.49 | +12.9% | +30.1% | +10.9% | +1.8% | +1.3% | -7.6% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.35 | $9.26 | -1.0% | -4.0% | +0.3% | +1.2% | +4.3% | -3.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Barinthus Biotherapeutics plc -- 8-K 5.02: Executive Change
Barinthus Biotherapeutics appointed Douglas Swirsky as Chief Financial Officer, a leadership change potentially signaling strategic financial direction for the biotech company's operations.
Apr 22
8-K
Barinthus Biotherapeutics plc -- 8-K Filing
Barinthus Biotherapeutics amended its merger agreement with Beacon on February 22, 2026, indicating modified deal terms that investors should review in full to understand potential impacts on the transaction completion and valuation.
Feb 23
Data updated apr 26, 2026 9:58am
· Source: massive.com